The characteristics of screening and confirmatory test results for HIV in Xi’an, China

Linchuan Wang1a, Kai-Hua Zhou2a, He-Ping Zhao3, Ji-Han Wang3, Hai-Chao Zheng4, Yan Yu3ab*, Wei Chen1a*

1 The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi Province, China, 2 Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi Province, China, 3 Honghui Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi Province, China, 4 Xi’an Center for Disease Control and Prevention, Xi’an, Shaanxi Province, China

☯ These authors contributed equally to this work.
¤ Current address: Xi’an, Shaanxi Province, China

Abstract

Objectives
Individuals with recent or acute HIV infection are more infectious than those with established infection. Our objective was to analyze the characteristics of detection among HIV infections in Xi’an.

Methods
A 4th-generation kit (Architect HIV Ag/Ab Combo) and three 3rd-generation EIA kits (WanTai, XinChuang and Livzon) were used for HIV screening. Overall, 665 individuals were identified as positive and were tested by western blotting (WB). The characteristics of the screening and confirmatory tests were analyzed, including the band patterns, the early detection performance and the false-positive rates.

Results
In total, 561 of the 665 patients were confirmed as having HIV-1 infection, and no HIV-2 specific band was observed. Among these 561 WB-positive cases, reactivity to greater than or equal to 9 antigens was the most commonly observed pattern (83.18%), and the absence of reactivity to p17, p31 and gp41 was detected in 6.44%, 5.9% and 2.86% of the cases, respectively. Two cases were positive by the 4th-generation assay but negative by the 3rd-generation assay for HIV screening and had seroconversion. The false-positive rate of the Architect HIV Ag/Ab Combo (22.01%) was significantly higher than those of WanTai (9.88%), XinChuang (10.87%) and Livzon (8.93%), p<0.05.

Conclusion
HIV infection in Xi’an is mainly caused by HIV-1, and individuals are rarely identified at the early phase. Although the false-positive rate of the 4th-generation assay was higher than that of the 3rd-generation assay, it is still recommended for use as the initial HIV screening...
test for high-risk individuals. In Xi’an, a 3rd-generation assay for screening could be considered.

Introduction

Since the first case of AIDS was identified in 1981 in the USA [1], HIV has spread at an alarming rate around the world, with approximately 36.9 million people infected worldwide [2]. Previous studies [3–5] have shown that individuals with recently or acutely acquired HIV are more infectious than those with established infection. Therefore, early screening tests for individuals in a high-risk setting are key to managing HIV infection. Tests for the screening and diagnosis of HIV infection have developed to the 5th generation over the past 3 decades [6, 7].

Currently, the 3rd- and 4th-generation assays are the preferred assays for HIV screening and diagnosis. The 3rd-generation assay can detect HIV-1/2 IgG/IgM antibodies within a window of approximately 3–4 weeks after exposure. The 4th-generation assay combines HIV-1/2 antibodies and p24 antigen detection with a window of approximately 2–3 weeks [6–9]. Although the p24 antigen is associated with acute HIV infection [9] and the 4th-generation assay has better sensitivity during early infection than the 3rd-generation assay [6–13], nonspecific reactions are often detected using the 4th-generation assay [14–18]. In the study, 665 patients were confirmed by WB at the Xi’an Center for Disease Control and Prevention (CDC), and we analyzed the characteristics of the screening test, the confirmatory test and the patients’ follow-up results.

Materials and methods

Study population

The study populations were from three hospitals in Xi’an, including the First Affiliated Hospital of Xi’an Jiaotong University, the Second Affiliated Hospital of Xi’an Jiaotong University and Shaanxi Province People’s Hospital. In accordance with the Chinese National guidelines for the detection of HIV/AIDS (2009), a total of 665 patients with positive HIV initial screening and retesting results in Xi’an in 2015 were included in the WB test at the Xi’an CDC. The median age was 36 years old (range: 7–86), and the male/female ratio was 565/100. Among the subjects, 309, 162, 138 and 56 patients were initially screened by the Architect HIV Ag/Ab Combo, WanTai, XinChuang and Livzon, respectively. The data from the initial screening, the duplicate retesting and the WB tests in the study were from the Xi’an CDC.

Third-generation assay

The three 3rd-generation kits, i.e., WanTai (WanTai Biological Pharmacy Enterprise Co, Ltd, Beijing, China), XinChuang (InTec Products, INC, XiaMen, Fujian, China) and Livzon (LivzonDiagnostics Inc., Zhuhai, China), were based on a double-Ag sandwich enzyme immunoassay to detect HIV-1/2 IgG and IgM antibodies. The HIV antigens of the kits are mixtures of HIV-1 gp120, HIV-1 gp41 and HIV-2 gp36. All tests were performed and interpreted in accordance with the manufacturer’s recommendations. An S/CO ≥1 and an S/CO<1 were defined as a positive result and a negative result, respectively.

Fourth-generation assay

The Architect HIV Ag/Ab Combo (Abbott Diagnostics, Abbott Park, IL) relies on a chemiluminescent immunoassay (CMIA) and was designed for the simultaneous detection of HIV-1
gp41 and HIV-2 gp36 antibodies and HIV-1 p24 antigen. The test was performed and interpreted in accordance with the manufacturer’s recommendations. A cut-off index (COI) \( \geq 1 \) and a COI \(< 1\) were defined as a positive result and a negative result, respectively.

**Western blot**

Western blot HIV1/2 BLOT 2.2 (MP Biomedicals, Singapore) is a confirmatory test for the HIV-1/2 antibody, with separated HIV-1 gene product groups of \( \text{gag} \) (p17, p24, p39, p55), \( \text{pol} \) (p31, p51, p66), \( \text{env} \) (gp120, gp160, gp41) and HIV-2-specific antigen immobilized on the membrane. The test was performed in accordance with the procedures described in the instructions. The results were interpreted according to the Chinese CDC criteria: a positive result required the presence of at least two bands, including two \( \text{env} \) bands (HIV-1: gp41 and gp120/gp160 and HIV-2: gp36 and gp105/gp140) or one \( \text{env} \) band and one p24 band. An indeterminate result was defined as the presence of a band profile that did not meet the positive criteria, and a negative result was the absence of any of the specific bands.

**Follow-up protocols**

For indeterminate or negative WB results, three WB tests were required at months 1, 3 and 6 of follow-up by the Chinese CDC. In our hospital, the follow-up protocols were as follows. (1) If the individual was not considered high-risk for HIV infection and the screening value ranged from 1 to 3 (3\(^{\text{rd}}\)-generation EIA) or 1 to 5 (4\(^{\text{th}}\)-generation assay), then three WB tests were performed at months 1, 3, and 6 of follow-up. (2) For an individual in a high-risk setting or with screening results \( \geq 3 \) (3\(^{\text{rd}}\)-generation EIA) or \( \geq 5 \) (4\(^{\text{th}}\)-generation assay), the WB test was performed at week 2, week 4, month 3 and month 6 of follow-up.

**Statistical analysis**

Statistical analyses were performed using SPSS 13.0 (serial number 5026743; SPSS Inc., Chicago, IL, USA), and the WB test was used as the gold standard in the study. Chi-square tests were used to compare the rates, and a p-value \(< 0.05\) was considered statistically significant.

**Ethics statement**

The study was deemed exempt from review by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University because of its retrospective nature.

**Results**

The comparison of the false-positive rate and the positive predictive value (PPV)

Overall, 559 of the 665 patients were confirmed as HIV antibody-positive by the initial WB test. All 79 patients with a WB-negative result and 25 of the 27 patients with a WB-indeterminate result were confirmed as negative by at least three WB tests. Two of the 27 patients with an indeterminate WB result (a gp120/gp160 band) had seroconversion. Overall, the PPVs of the Architect HIV Ag/Ab Combo, WanTai, XinChuang and Livzon were 77.99%, 90.12%, 89.13%, and 91.07%, respectively. Comparing the false-positive rates of the four kits, no significant differences were observed among the three 3\(^{\text{rd}}\)-generation kits \( p > 0.05\), but the false-positive rate of the Architect HIV Ag/Ab Combo (22.01%) was significantly higher than those of WanTai (9.88%), XinChuang (10.87%) and Livzon (8.93%), \( p < 0.05\) (Fig 1A and Table 1).
The characteristics of the western blot band profiles

A total of 559 patients were confirmed as HIV-1 antibody-positive by the initial WB test, and the HIV-2-specific band was not observed in the study. Among the results, 11 band patterns were detected. Reactivity to all of the bands was the most commonly observed pattern (53.13%), reactivity to 9 antigens (absence of reactivity to p39) was observed in 30.05% of the cases, and the absence of reactivity to p17, p31 and gp41 was noted in 6.44%, 5.9% and 2.86% of the cases, respectively. The characteristics of the band profiles showed that the majority of the patients in the study had established HIV infections. The detection rates for the gp160/gp120, gp41, p66, p51, p31, p24, p17, p39 and p55 bands were 100% (559/559), 97.14% (543/559), 96.42% (539/559), 95.89% (536/559), 94.1% (526/559), 100% (559/559), 93.56% (523/559), 53.13% (297/559) and 83.18% (465/559), respectively (Table 2, Fig 1B). A total of 27 patients with a sole band were identified as indeterminate in the initial WB test. The p24 band was detected in 21 patients, and the gp120/gp160 band was detected in 6 cases.

Table 1. The results of Western blot and follow-up.

| screening positive n = 665 | Western blot |
|---------------------------|--------------|
|                           | Positive, n(%) | Negative, n(%) | Indeterminate, n(%) |
| Abbott (n = 309)           | 240 (77.67%)   | 54 (17.48%)    | 15 (4.85%)*         |
| WanTai (n = 162)           | 145 (89.51%)   | 9 (5.56%)      | 8 (4.94%)*          |
| XinChuang (n = 138)        | 123 (89.13%)   | 13 (9.42%)     | 2 (1.45%)           |
| Livzon (n = 56)            | 51 (91.07%)    | 3 (5.36%)      | 2 (3.57%)           |

https://doi.org/10.1371/journal.pone.0180071.t001
Patients with a WB-negative result or with a WB-indeterminate result

In the study, 79 and 27 patients, respectively, were identified as negative and indeterminate by the first WB. Among these subjects, 87 patients did not seroconvert according to three WB tests (months 1, 3 and 6), 17 of the 19 patients in high-risk settings were confirmed as negative through four WB tests (week 2, week 4, month 3 and month 6), and 2 of the 19 patients in high-risk settings showed seroconversion by WB retesting at week 2.

Case 1: the first screening was negative by XinChuang (0.61), but 2 days later, the retesting on another sample was positive using WanTai (3.06), Livzon (5.79) and the Architect HIV Ag/Ab Combo (64.33) but negative by XinChuang (0.8). The gp120/gp160 band in the first WB test and the p24, p66, gp41, and gp120/gp160 bands in the second WB test one week later were observed. Case 2: the first sample tested positive by the Architect HIV Ag/Ab Combo (12.57) but retested as negative using XinChuang (0.17). One week later, another sample was positive in both XinChuang (12.17) and the Architect HIV Ag/Ab Combo (127.81). The gp120/gp160 band for the first WB and p24, p31, p51, gp41, and gp120/gp160 bands for the second test one week later were observed.

The consistency and PPV of the four kits at different screening values

When the Architect HIV Ag/Ab Combo screening positive cases were retested using a 3rd-generation kit, at COI values of 1–5, 5–30 and ≥ 30, the consistencies were 6.82%, 64.1% and 100%, respectively. When the 3rd-generation kits were used for both screening and retesting, at screening S/CO ratios of 1–3, 3–10 and ≥10 for WanTai, the consistencies were 23.08%, 40% and 100%, respectively. For XinChuang, they were 20%, 46.88% and 100%, and for Livzon, they were 20%, 37.5% and 100%, respectively (Table 3).

In the first WB, at COI < 5 or S/CO < 3 and at COI ≥30 or S/CO ≥10, all of the patients were found negative and positive, respectively (Fig 2). When the screening values for the Architect HIV Ag/Ab Combo were 1–5, 5–30 and ≥30, the corresponding PPVs were 0, 38.64%, and 100%. At S/CO ratios of 1–3 and ≥10, the PPVs of the 3rd-generation kits were 0 and 100%, respectively. At S/CO ratios of 3–10, the PPVs of WanTai, XinChuang and Livzon were 50%, 58.82% and 95%. In the study, 63.46% (66/104) of the false-positive results were distributed at COI 1–5 or S/CO 1–3 (Table 3).

Discussion

To determine whether an individual is infected with HIV, an initial screening test, duplicate retests and confirmatory tests should be performed. People are often concerned about the

| WB band profile | Frequency (n = 559) | Abbott | WanTai | XinChuang | Livzon |
|-----------------|---------------------|--------|---------|------------|--------|
| p24 p17 p55 p39 p31 p51 p66 gp41 gp120/gp160 | 125 | 80 | 60 | 32 |
| p24 p17 p55 p31 p51 p66 gp41 gp120/gp160 | 67 | 50 | 39 | 12 |
| p24 p17 p31 p51 p66 gp41 gp120/gp160 | 29 | 10 | 13 | 3 |
| p24 p31 p51 p66 gp41 gp120/gp160 | 4 | 0 | 1 | 0 |
| p24 p17 p51 p66 gp41 gp120/gp160 | 1 | 0 | 0 | 2 |
| p24 p51 p66 gp41 gp120/gp160 | 2 | 2 | 2 | 0 |
| p24 p31 p51 gp41 gp120/gp160 | 0 | 0 | 0 | 1 |
| p24 p66 gp41 gp120/gp160 | 3 | 1 | 1 | 0 |
| p24 p51 gp41 gp120/gp160 | 0 | 1 | 0 | 0 |
| p24 gp41 gp120/gp160 | 1 | 1 | 0 | 0 |
| p24 gp120/gp160 | 8 | 0 | 7 | 1 |

https://doi.org/10.1371/journal.pone.0180071.t002
specificity of HIV screening kits. Currently, antigens such as gp41 and gp36 (Abbott Architect HIV Ag/Ab Combo and Roche Elecsys HIV Combi), gp120, gp41 and gp36 (domestic kit and Bayer ADVIA centaurg HIV 1/O/2 enhanced), gp160, gp41 and gp36 (Genscreen™ ULTRA and VIDAS DUO Ultra) are usually used to detect HIV-1/2 antibodies \[13, 19, 20\] with excellent sensitivity \[8, 10–13, 19, 21, 22\]. Many factors, such as influenza vaccination \[14,15\], rheumatoid factors, autoimmune diseases \[15\], parasitic infection \[16\], and pregnancy \[18\], may lead to poor specificity in HIV screening by the 4\textsuperscript{th}-generation assay and an indeterminate result for the WB test \[23, 24\].

Jensen et al \[25\] reported that the false-positive rate of the Architect HIV Ag/Ab Combo was 31.39\% (1163/3705). In our study it was 22.01\% (68/309) but was significantly higher than the 3\textsuperscript{rd}-generation kit, which was consistent with previous reports \[21, 26\]. We found that higher screening values were correlated with an increased consistency and PPV. In the study, 63.46\% of the false-positive results were distributed at COI 1–5 or S/CO 1–3. When the screening values were at COI values \(\geq 30\) or S/CO ratios \(\geq 10\), the consistency and PPV were both 100\%. However, at COI < 5 or S/CO < 3, the PPV was 0, and the consistency was only 6.82\% – 23.08\%.

Previous studies \[27, 28, 29\] have shown that the variations in the WB band pattern were associated with the stages of HIV infection. Antibodies to gag antigens were detectable earlier than were antibodies to env antigens \[27, 28\]. The absence of reactivity to gag antigen p17, pol antigen p31\[27\] or env antigen gp41 \[30\] were often observed among seroconverters. WB profiles with the presence of p17 may constitute a predictor of established HIV infection \[27\]. In the study, reactivity to more than or equal to 9 antigens was the most commonly observed WB pattern, occurring in 83.18\% of cases, and the absence of reactivity to p17, p31 and gp41 antigens was noted in only 6.44\%, 5.9\% and 2.86\% of cases. According to the criteria of Fiebig et al \[29\], 2, 33 and 526 of the 561 HIV infection cases in this study can be classified as stage IV, V and VI, respectively, implying that the HIV infections in Xi’an were rarely detected at the early

| Screening positive | Retesting positive | Consistency | Western blot confirmed |
|--------------------|--------------------|-------------|------------------------|
| Used kit           | Value | Number | Number | FP(n) | TP(n) | PPV(%) |
| Architect HIV Ag/Ab Combo | 1.00–5.00 | 44 | 3 | 6.82 | 44 | 0 | 0 |
|                     | 5.00–30.00 | 39 | 25 | 64.1 | 24 | 15 | 38.46 |
|                     | \(\geq 30.00\) | 226 | 226 | 100 | 0 | 226 | 100 |
| WanTai             | 1.00–3.00 | 10 | 3 | 23.08 | 10 | 0 | 0 |
|                     | 3.00–10.00 | 12 | 8 | 40 | 6 | 6 | 50 |
|                     | \(\geq 10.00\) | 140 | 140 | 100 | 0 | 140 | 100 |
| XinChuang          | 1.00–3.00 | 8 | 2 | 20 | 8 | 0 | 0 |
|                     | 3.00–10.00 | 17 | 15 | 46.88 | 7 | 10 | 58.82 |
|                     | \(\geq 10.00\) | 113 | 113 | 100 | 0 | 113 | 100 |
| Livzon             | 1.00–3.00 | 4 | 1 | 20 | 4 | 0 | 0 |
|                     | 3.00–10.00 | 20 | 12 | 37.5 | 1 | 19 | 95 |
|                     | \(\geq 10.00\) | 32 | 32 | 100 | 0 | 32 | 100 |

Note: FP was false positive; TP was true positive.

https://doi.org/10.1371/journal.pone.0180071.t003
phase. The absence of reactivity to p39 or p55 antigens may be associated with disease progression [27]. In our study, p39 and p55 bands were not observed in 46.87% and 16.82% of the HIV infections. Published results reported that gp160 and gp120 may be used as earlier antigens to detect the HIV antibody [28, 31–33]. In Saah et al study [28], the gp120/160 band was detected more early than gp41 band in HIV infections at the early phase, and 20 of the 23 gp41-negative cases were identified as having anti-envelope antibodies (gp120/160). In our study, the detection rates of gp41 and gp160/gp120 bands in the HIV infections were 97.14% and 100%.

In the study, two cases with reactivity to gp120/gp160 had seroconversion at follow-up week 2, and they tested positive by the 4th-generation assay but negative by the 3rd-generation assay. This also confirmed that the addition of p24 antigen detection to the 4th-generation assay results in an earlier detection of HIV-1 infection compared to the 3rd-generation assay [34]. Currently, in China, if the WB test is indeterminate or negative for individuals with positive screening results, then three WB tests are required. Although most of these individuals are not infected with HIV, seroconversion [27, 28] may occur. Therefore, the current follow-up protocol in China is not suitable for all individuals. In particular, in individuals with a gp120/gp160 band or recent HIV exposure, frequent WB retesting during the first follow-up month, at weeks 2 and 4 for example, is needed.
China is a country that is characterized by income inequality and a low HIV prevalence. Both the 3rd- and 4th-generation assays are commonly used for HIV screening. The appropriate selection of the first HIV test is important. In non-high-risk settings, inexpensive 3rd-generation EIA assays with reduced false-positive results are advantageous. For the high-risk population, the 4th-generation assay is recommended as the initial HIV screening method to improve the detection rate at the early phase of HIV infection. In individuals who are positive for the gp120/gp160 WB band (suspicious for recent HIV exposure), two WB tests at the first month of follow-up are needed.

Supporting information

S1 File. The original data of the initial screening, retesting and WB tests in the study. The data that processed anonymously were from the Xian Center for Disease Control and Prevention (CDC).

Author Contributions

Conceptualization: Linchuan Wang, Yan Yu.
Formal analysis: Kai-Hua Zhou, Ji-Han Wang, Wei Chen.
Funding acquisition: Yan Yu.
Investigation: Linchuan Wang, He-Ping Zhao, Hai-Chao Zheng.
Methodology: Linchuan Wang.
Project administration: Yan Yu.
Supervision: Linchuan Wang.
Validation: Linchuan Wang, Yan Yu.
Visualization: Yan Yu.
Writing – original draft: Linchuan Wang.
Writing – review & editing: Yan Yu.

References

1. Rickman LS. Pneumocystis pneumonia—Los Angeles: Centers for Disease Control. MMWR 1981; 30:250–2. PMID: 6265753
2. World Health Organization, HIV/AIDS. www.who.int/hiv/en/, 2015.
3. Shaw GM, Hunter E. HIV transmission. Cold Spring Harbor Perspectives in Medicine. 2012; 2(11):705–9.
4. Stekler J, Maenza J, Stevens CE, Swenson PD, Coombs RW, Wood RW, et al. Screening for acute HIV infection: lessons learned. Clinical Infectious Diseases An Official Publication of the Infectious Diseases Society of America. 2007; 44(3):459–61. https://doi.org/10.1086/510747 PMID: 17205460
5. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. Journal of Infectious Diseases. 2005; 191(9):1403–9. https://doi.org/10.1086/429411 PMID: 15809897
6. Alexander TS. Human Immunodeficiency Virus Diagnostic Testing: 30 years of Evolution. Clinical & Vaccine Immunology. 2016; 23(4):249–53.
7. Salmora M, Delarue S, Delaugerre C, Simon F, Maylin S. Clinical evaluation of BioPlex 2200 HIV Ag-Ab, an automated screening method providing discrete detection of HIV-1 p24 antigen, HIV-1 antibody, and HIV-2 antibody. Journal of Clinical Microbiology. 2014; 52(1):103–7. https://doi.org/10.1128/JCM.02460-13 PMID: 24153130
23. Grusky O, Roberts KJ, Swanson AN. Communicating indeterminate HIV Western blot test results to clients. Journal of Clinical Virology. 2013; 58 (Supplement 1):e79–e84.

24. Weber B, Berger A, Rabenau H, Doerr HW. Evaluation of a new combined antigen and antibody human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. Journal of Clinical Microbiology. 2009; 47(8):2639–42. https://doi.org/10.1128/JCM.00119-09 PMID: 19536523

25. Weber B, Berger A, Rabenau H, Doerr HW. Evaluation of a new combined antigen and antibody human immunodeficiency virus screening assay, VIDAS HIV DUO Ultra. Journal of Clinical Microbiology. 2002; 40(4):1420–6. https://doi.org/10.1128/JCM.40.4.1420-1426.2002 PMID: 11923967

26. Erickson CP, McNiff T, Klausner JD. Influenza vaccination and false positive HIV results. New England Journal of Medicine. 2006; 354(13):1422–3. https://doi.org/10.1056/NEJMoa053417 PMID: 16571889

27. Everett DB, Weiss HA, Changalucha J, Anemona A, Chirwa T, Ross DA, et al. Low specificity of the Murex fourth-generation HIV enzyme immunoassay in Tanzanian adolescents. Tropical Medicine & International Health. 1989; 12(11):1323–6.

28. Kim S, Lee JH, Choi JY, Kim JM, Kim HS. False-positive rate of a “fourth-generation” HIV antigen/antibody combination assay in an area of low HIV prevalence. Clinical & Vaccine Immunology. 2010; 17 (10):46.

29. Mahajan VS, Pace CA, Jarolim P. Interpretation of HIV serologic testing results. Clinical Chemistry. 2010; 56(10):1523–6. https://doi.org/10.1373/clinchem.2009.139535 PMID: 20876778

30. Shimasano T, Yamada R, Sekita K, Hankins RW, Hori H, Seto H, et al. A human immunodeficiency virus screening algorithm to address the high rate of false-positive results in pregnant women in Japan. Plos One. 2009; 5(2): e9382.

31. Fanmi AN, Ramière C, Tardy JC, André P. Real-life evaluation of a human immunodeficiency virus screening algorithm using a single combined p24 antigen–antibody assay. European Journal of Clinical Microbiology & Infectious Diseases. 2013; 32(3):425–30.

32. Ly TD, Ebel A, Faucher V, Fihman V, Laperche S. Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays? Journal of Virological Methods. 2007; 143(1):86–94. https://doi.org/10.1016/j.jviromet.2007.02.013 PMID: 17395277

33. Dubravac T, Gahan TF, Pentella MA. Use of the Abbott Architect HIV antigen/antibody assay in a low incidence population. Journal of Clinical Virology the Official Publication of the Pan American Society for Clinical Virology. 2013; 58 (Suppl 1):e76–e8.

34. Schappert J, Wians FH, Schiff E, Smalley D, Gambardella R, Lee WM, et al. Multicenter Evaluation of the Bayer ADVIA Centaur® HIV 1/O Enhanced (EHIV) Assay ☆. Clinica Chimica Acta. 2006; 372(1–2):158–66.

35. Grusky O, Roberts KJ, Swanson AN. Communicating indeterminate HIV Western blot test results to clients: an observational study of three community testing sites. Aids Patient Care & Stds. 2006; 20 (9):620–7.

36. Guan M. Frequency, Causes, and New Challenges of Indeterminate Results in Western Blot Confirmatory Testing for Antibodies to Human Immunodeficiency Virus. Clinical & Vaccine Immunology. 2007; 14(6):649–59.

37. Jensen TO, Robertson P, Whybin R, Chambers I, Lahra M, Rawlinson W, et al. A signal-to-cutoff ratio in the Abbott architect HIV Ag/Ab Combo assay that predicts subsequent confirmation of HIV-1 infection in a low-prevalence setting. Journal of Clinical Microbiology. 2015; 53(5):1709–11. https://doi.org/10.1128/JCM.03583-14 PMID: 25673794

38. Ly T, C, Vabret A. Contribution of combined detection assays of p24 antigen and anti-human immunodeficiency virus (HIV) antibodies in diagnosis of primary HIV infection by routine testing (letter). Journal of Clinical Microbiology. 2000; 38(6):2459–61. PMID: 10917776
27. Duri K, Müller F, Gumbo FZ, Kurewa NE, Rusakaniko S, Chirenje MZ, et al. Human Immunodeficiency Virus (HIV) types Western blot (WB) band profiles as potential surrogate markers of HIV disease progression and predictors of vertical transmission in a cohort of infected but antiretroviral therapy naive pregnant women in Harare, Z. Bmc Infectious Diseases. 2011; 11(1):1–8.

28. Saah AJ, Farzadegan H, Fox R, Nishanian P, RC Jr, Phair JP, et al. Detection of early antibodies in human immunodeficiency virus infection by enzyme-linked immunosorbent assay, Western blot, and radioimmunoprecipitation. Journal of Clinical Microbiology. 1987; 25(9):1605–10. PMID: 3477569

29. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. Aids. 2003; 17(13):1871–9. https://doi.org/10.1097/01.aids.0000076308.76477.b8 PMID: 12960819

30. Wang JB, Zhang N, Yu HY, Li YL, Duan X, Yan H, et al. [Study on the role of western blot band profile for the detection of recent HIV infection]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2013; 34(10):998–1002. PMID: 24377995

31. Chen J, Wang L, Chen JJ, Sahu GK, Tyring S, Ramsey K, et al. Detection of antibodies to human immunodeficiency virus (HIV) that recognize conformational epitopes of glycoproteins 160 and 41 often allows for early diagnosis of HIV infection. Journal of Infectious Diseases. 2002; 186(3):321–31. https://doi.org/10.1086/341661 PMID: 12134228

32. Talha SM, Kumar NS, Teppo S, Sushil K, Sathyamangalam S, Tero S, et al. Escherichia coli-expressed near full length HIV-1 envelope glycoprotein is a highly sensitive and specific diagnostic antigen. Bmc Infectious Diseases. 2012; 12(18):: 325.

33. Talha SM, Salminen T, Swaminathan S, Soukka T, Pettersson K, Khanna N. A highly sensitive and specific time resolved fluorometric bridge assay for antibodies to HIV-1 and -2. Journal of Virological Methods. 2011; 173(1):24–30. https://doi.org/10.1016/j.jviromet.2011.01.001 PMID: 21232554

34. Wang L, Chen W, Yu Y. The Performance of the Abbott i2000 for Measuring Serum Markers of Infectious Diseases. Journal of Clinical Laboratory Analysis. 2017; 31(1):e22015.